{"entity":{"id":"rejoice-ovarian01","kind":"trial","name":"REJOICE-Ovarian01","aka":[],"tldr":"Tests whether a CDH6-targeting ADC with Enhertu's payload can beat chemotherapy in resistant ovarian cancer.","summary":"REJOICE-Ovarian01, trial NCT06161025 sponsored by Daiichi Sankyo and Merck, is the phase 2/3 test of whether raludotatug deruxtecan, a CDH6-targeting antibody-drug conjugate carrying the same payload as trastuzumab deruxtecan, can beat physician's choice chemotherapy in platinum-resistant ovarian cancer after one to three prior lines. The phase 2 dose-optimisation part reported an objective response rate of 50.5 percent at ESMO 2025, the phase 3 part randomises at 5.6 mg/kg against chemotherapy, and readout is expected in 2026 to 2027. OnCo links it to ovarian cancer, antibody-drug conjugates, CDH6 as a target and raludotatug deruxtecan. Whether a new ADC target can match mirvetuximab's survival benefit, and in which patients, is the question it will answer.","status":"recruiting","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT06161025","url":"https://clinicaltrials.gov/study/NCT06161025"}],"tags":[],"related":[],"cancers":["ovarian"],"sections":[],"technologies":["adc"],"targets":["cdh6"],"drugs":["raludotatug-deruxtecan"],"companies":["daiichi-sankyo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06161025","phase":"2/3","setting":"Platinum-resistant ovarian cancer, 1-3 prior lines: raludotatug deruxtecan (CDH6 ADC) vs physician's-choice chemotherapy","sponsor":"Daiichi Sankyo / Merck","result":"Phase 2 ORR 50.5%; phase 3 ongoing.","started":"2024-02-27","startedType":"actual","enrolledBasis":"registry","outcomes":[{"endpoint":"Objective response rate (phase 2 part)","unit":"%","arms":[{"name":"R-DXd","value":50.5}],"source":"https://www.merck.com/news/raludotatug-deruxtecan-demonstrated-clinically-meaningful-response-rates-in-patients-with-recurrent-platinum-resistant-ovarian-primary-peritoneal-or-fallopian-tube-cancer-in-phase-2-part-of-rejoice-o/"}]},"route":"/trials/rejoice-ovarian01/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"cdh6","kind":"target","name":"CDH6","route":"/targets/cdh6/"}],"drug":[{"id":"raludotatug-deruxtecan","kind":"drug","name":"Raludotatug deruxtecan","route":"/drugs/raludotatug-deruxtecan/"}],"company":[{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"}],"term":[{"id":"dose-escalation-design","kind":"term","name":"Dose-escalation designs (3+3, BOIN, dose-expansion)","route":"/terms/dose-escalation-design/"},{"id":"trial-phases","kind":"term","name":"Phase 1, 2 and 3 trials","route":"/terms/trial-phases/"},{"id":"project-optimus","kind":"term","name":"Project Optimus","route":"/terms/project-optimus/"},{"id":"seamless-adaptive","kind":"term","name":"Seamless, adaptive and Bayesian trial designs","route":"/terms/seamless-adaptive/"}]}}